Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cholesterol-lowering combo also shrink fatty liver in diabetic heart patients?

NCT ID NCT07736313

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial investigates whether adding a PCSK9 inhibitor to a high-intensity statin can reduce liver fat—measured by a non-invasive FibroScan—in diabetic patients who have recently had a heart attack or unstable angina. Half the participants will receive the combination therapy, while the other half receive the statin alone. The goal is to see if the combination offers additional benefits for liver health and cholesterol control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a PCSK9 inhibitor (a cholesterol-lowering drug) plus rosuvastatin 20 mg tablet
What this could lead to
If it works, this could point toward a way to both lower cholesterol and reduce liver fat in diabetic heart patients, potentially lowering their risk of future heart problems.
What could go wrong
This is a small, early-phase trial (120 people) focused on a liver fat measurement, not on actual heart events. The added benefit over statins alone may be modest, and PCSK9 inhibitors can cause injection-site reactions or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18y.o 2. Any patient presented with acute coronary syndromes (Myocardial infarction (MI), non-ST elevation Myocardial infarction (NSTEMI), unstable angina) underwent coronary angiography within admission. 3. Patients must be diabetic. 4. Statin naïve patients at the time of enrollment. Exclusion Criteria: 1. patients \> 18 y.o 2. Patients who have chronic liver disease other than MASLD 3. Patients having liver neoplasm 4. Patient refused

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.